German researchers have determined the mechanism of a ADEPs, a novel class of antibiotics, allowing for pharmacological optimisation.

A new method allows real-time-visualisation of how the HI virus spreads between living T helper cells and which molecules it requires for this purpose.

How can biotechnology and bioeconomy contribute to establish a sustainable and circular economy? Nearly 500 attendees discussed latest trends at EFIB 2019 in Brussels. 

Rottapharm Biotech (Monza, Italy) has published detailed results from a clinical Phase II trial of CR4056 in chronic pain from knee osteoarthritis.

H.E.L. Group Ltd has a new CEO: The global manufacturer of laboratory tools for process optimisation, safety and scale-up announced the appointment of Louise Madden as Chief Executive Officer.

Spain’s biotech association Asebio announced new record numbers from its biotech investor day held as part of the European Biotech Week.

Swiss drug discovery analytics specialist Creoptix AG has raised CHF8m in a Series C financing for commercial expansion.

 Edwin Klumper of Lytix Biopharma has stepped down from his role as CEO. The board has decided to promote Head of R&D Øystein Rekdal to the position of CEO.

Entasis Therapeutics Inc (Waltham, USA) and non for profit organisation GARDP (Geneva, Switzerland) have initiated Phase III testing of the novel antibiotic zoliflodacin to treat infections with the WHO priority pathogen N. gonorrhoea.

British cell therapy expert Mogrify Ltd has appointed Jane Osbourn as Chair of the Board. Osbourn will also become a Member of the Scientific Advisory Board and support Mogrifiy’s executive team in therapeutic programme selection, industrial partner development, mentoring and investor relations.